modelPhenindione
Extends from Pharmacolibrary.Drugs.ATC.B.B01AA02.
Information
| name: | Phenindione | |
| ATC code: | B01AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 2.6 | L/h |
| other parameters in model implementation | ||
Phenindione is an oral anticoagulant medication, acting as a vitamin K antagonist, formerly used for the prevention and treatment of thromboembolic disorders. Due to concerns about adverse reactions such as hypersensitivity and the availability of safer alternatives (e.g., warfarin), it is largely obsolete and is not commonly approved or used today.
Pharmacokinetics
Pharmacokinetic estimates based on limited literature and secondary drug databases, typical values represent healthy adult volunteers after oral administration.
References
Comets, E, et al., & Mentré, F (2012). Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clinical pharmacology and therapeutics 91(5) 777–786. DOI:10.1038/clpt.2011.309 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22472992
Mentré, F, et al., & Lechat, P (1998). Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clinical pharmacology and therapeutics 63(1) 64–78. DOI:10.1016/S0009-9236(98)90122-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9465843
Verstuyft, C, et al., & Becquemont, L (2012). A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clinical pharmacokinetics 51(1) 41–53. DOI:10.2165/11595560-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149257
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)